Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
about
The role of surgeons in building a personalized medicine programUnveiling changes in the landscape of patient populations in cancer early drug developmentEvaluating the feasibility of performing window of opportunity trials in breast cancer.Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.Rethinking ovarian cancer: recommendations for improving outcomes.A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsPreoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationPredictors of willingness to participate in window-of-opportunity breast trialsTranslating metastasis-related biomarkers to the clinic--progress and pitfalls.Suitable trial designs and cohorts for preventive breast cancer agents.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Novel treatment concepts in Hodgkin lymphoma.Proteomics and phosphoproteomics in precision medicine: applications and challenges.Clinical trial design in brain metastasis: approaches for a unique patient population.An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.Molecular prescreening to select patient population in early clinical trials
P2860
Q26849667-443DF457-C0BF-49CB-9FDD-FA363F9EB5F0Q28073826-63ABC2B6-8B28-406E-BFD1-2F28C60DB614Q35061474-A325D6C9-ED31-4ABF-A2E7-730FBBD0C5FEQ35583876-D5982486-3DAE-4E4A-9AE8-FA324934518DQ36050883-5B1553DC-644C-4006-98F9-E46FA388237AQ36106434-F813D2CD-92FD-4389-BFAD-D740B0B42FA4Q36472317-79D80162-F28A-4CBE-A106-D5289D2F5251Q36565598-90C02B90-847A-40FF-A590-ABAEF5D8BA7AQ37210705-78894EC0-753E-4A23-B02B-EFFCA765D10FQ38079125-012BC330-3DEA-488E-A466-7614644D9701Q38150222-69FCD476-AEBB-416C-BF70-880E7986EB84Q38906990-930A9FDD-0789-4817-B69A-7F24C32C5690Q39043082-CB70F626-6804-4EBA-B00C-FBDF5F1A0305Q47595178-220DB9A2-9CF9-49DB-AF9F-DF37D1A69EEEQ48806386-8EA7C0C7-75C0-46EB-BFE6-C560B2D8A4EFQ54351338-1093C822-4695-4C60-AD16-A3C1FFC0718FQ58614572-A89863ED-1703-40F3-8E16-0A62E2258D0E
P2860
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Window-of-opportunity trials t ...... olecular entities in oncology.
@en
Window-of-opportunity trials t ...... olecular entities in oncology.
@nl
type
label
Window-of-opportunity trials t ...... olecular entities in oncology.
@en
Window-of-opportunity trials t ...... olecular entities in oncology.
@nl
prefLabel
Window-of-opportunity trials t ...... olecular entities in oncology.
@en
Window-of-opportunity trials t ...... olecular entities in oncology.
@nl
P356
P1433
P1476
Window-of-opportunity trials t ...... olecular entities in oncology.
@en
P2093
P304
P356
10.1093/ANNONC/MDQ622
P577
2011-01-13T00:00:00Z